52 related articles for article (PubMed ID: 12649158)
1. Genetically targeted radiotherapy for multiple myeloma.
Dingli D; Diaz RM; Bergert ER; O'Connor MK; Morris JC; Russell SJ
Blood; 2003 Jul; 102(2):489-96. PubMed ID: 12649158
[TBL] [Abstract][Full Text] [Related]
2. Feasibility of adenovirus-mediated hNIS gene transfer and 131I radioiodine therapy as a definitive treatment for localized prostate cancer.
Barton KN; Stricker H; Elshaikh MA; Pegg J; Cheng J; Zhang Y; Karvelis KC; Lu M; Movsas B; Freytag SO
Mol Ther; 2011 Jul; 19(7):1353-9. PubMed ID: 21587209
[TBL] [Abstract][Full Text] [Related]
3. Non-overlapping Control of Transcriptome by Promoter- and Super-Enhancer-Associated Dependencies in Multiple Myeloma.
Fulciniti M; Lin CY; Samur MK; Lopez MA; Singh I; Lawlor MA; Szalat RE; Ott CJ; Avet-Loiseau H; Anderson KC; Young RA; Bradner JE; Munshi NC
Cell Rep; 2018 Dec; 25(13):3693-3705.e6. PubMed ID: 30590042
[TBL] [Abstract][Full Text] [Related]
4. Radiovirotherapy at twenty.
Dingli D
Mol Ther Oncolytics; 2023 Jun; 29():127-128. PubMed ID: 37260766
[No Abstract] [Full Text] [Related]
5. Vaccinia virus and peptide-receptor radiotherapy synergize to improve treatment of peritoneal carcinomatosis.
Ottolino-Perry K; Mealiea D; Sellers C; Acuna SA; Angarita FA; Okamoto L; Scollard D; Ginj M; Reilly R; McCart JA
Mol Ther Oncolytics; 2023 Jun; 29():44-58. PubMed ID: 37180034
[TBL] [Abstract][Full Text] [Related]
6. Stable HIV decoy receptor expression after in vivo HSC transduction in mice and NHPs: Safety and efficacy in protection from SHIV.
Li C; Anderson AK; Wang H; Gil S; Kim J; Huang L; Germond A; Baldessari A; Nelson V; Bar KJ; Peterson CW; Bui J; Kiem HP; Lieber A
Mol Ther; 2023 Apr; 31(4):1059-1073. PubMed ID: 36760126
[TBL] [Abstract][Full Text] [Related]
7. Applications of nuclear-based imaging in gene and cell therapy: probe considerations.
Volpe A; Pillarsetty NVK; Lewis JS; Ponomarev V
Mol Ther Oncolytics; 2021 Mar; 20():447-458. PubMed ID: 33718593
[TBL] [Abstract][Full Text] [Related]
8. Tumor microenvironment affects exogenous sodium/iodide symporter expression.
Castillo-Rivera F; Ondo-Méndez A; Guglielmi J; Guigonis JM; Jing L; Lindenthal S; Gonzalez A; López D; Cambien B; Pourcher T
Transl Oncol; 2021 Jan; 14(1):100937. PubMed ID: 33217645
[TBL] [Abstract][Full Text] [Related]
9.
Kemler I; Ennis MK; Neuhauser CM; Dingli D
Mol Ther Oncolytics; 2019 Mar; 12():68-78. PubMed ID: 30705967
[TBL] [Abstract][Full Text] [Related]
10. Human sodium iodide transporter gene-mediated imaging and therapy of mouse glioma, comparison between
Guo R; Xi Y; Zhang M; Miao Y; Zhang M; Li B
Oncol Lett; 2018 Mar; 15(3):3911-3917. PubMed ID: 29467904
[TBL] [Abstract][Full Text] [Related]
11. Regression of experimental NIS-expressing breast cancer brain metastases in response to radioiodide/gemcitabine dual therapy.
Renier C; Do J; Reyna-Neyra A; Foster D; De A; Vogel H; Jeffrey SS; Tse V; Carrasco N; Wapnir I
Oncotarget; 2016 Aug; 7(34):54811-54824. PubMed ID: 27363025
[TBL] [Abstract][Full Text] [Related]
12. Establishment of an Effective Radioiodide Thyroid Ablation Protocol in Mice.
Schmohl KA; Müller AM; Schwenk N; Knoop K; Rijntjes E; Köhrle J; Heuer H; Bartenstein P; Göke B; Nelson PJ; Spitzweg C
Eur Thyroid J; 2015 Sep; 4(Suppl 1):74-80. PubMed ID: 26601076
[TBL] [Abstract][Full Text] [Related]
13. Theranostic studies of human sodium iodide symporter imaging and therapy using 188Re: a human glioma study in mice.
Guo R; Zhang M; Xi Y; Ma Y; Liang S; Shi S; Miao Y; Li B
PLoS One; 2014; 9(7):e102011. PubMed ID: 25000403
[TBL] [Abstract][Full Text] [Related]
14. Sodium iodide symporter and the radioiodine treatment of thyroid carcinoma.
Chung JK; Youn HW; Kang JH; Lee HY; Kang KW
Nucl Med Mol Imaging; 2010 Apr; 44(1):4-14. PubMed ID: 24899932
[TBL] [Abstract][Full Text] [Related]
15. Gene delivery in malignant B cells using the combination of lentiviruses conjugated to anti-transferrin receptor antibodies and an immunoglobulin promoter.
Leoh LS; Morizono K; Kershaw KM; Chen IS; Penichet ML; Daniels-Wells TR
J Gene Med; 2014; 16(1-2):11-27. PubMed ID: 24436117
[TBL] [Abstract][Full Text] [Related]
16. The Na+/I- symporter (NIS): mechanism and medical impact.
Portulano C; Paroder-Belenitsky M; Carrasco N
Endocr Rev; 2014 Feb; 35(1):106-49. PubMed ID: 24311738
[TBL] [Abstract][Full Text] [Related]
17. Objective assessment of image quality VI: imaging in radiation therapy.
Barrett HH; Kupinski MA; Müeller S; Halpern HJ; Morris JC; Dwyer R
Phys Med Biol; 2013 Nov; 58(22):8197-213. PubMed ID: 24200954
[TBL] [Abstract][Full Text] [Related]
18. Curative one-shot systemic virotherapy in murine myeloma.
Naik S; Nace R; Federspiel MJ; Barber GN; Peng KW; Russell SJ
Leukemia; 2012 Aug; 26(8):1870-8. PubMed ID: 22425894
[TBL] [Abstract][Full Text] [Related]
19. The sodium iodide symporter (NIS) as an imaging reporter for gene, viral, and cell-based therapies.
Penheiter AR; Russell SJ; Carlson SK
Curr Gene Ther; 2012 Feb; 12(1):33-47. PubMed ID: 22263922
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of lentiviral-mediated expression of sodium iodide symporter in anaplastic thyroid cancer and the efficacy of in vivo imaging and therapy.
Ke CC; Hsieh YJ; Hwu L; Wang FH; Chen FD; Chu LS; Lee OK; Chi CW; Lee CH; Liu RS
J Oncol; 2011; 2011():178967. PubMed ID: 22220168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
